Shrinks In Sneakers

Tag: neuroprotective

  • Can β-Blockers Really Delay the Onset and Progression of Huntington’s Disease?

    Can β-Blockers Really Delay the Onset and Progression of Huntington’s Disease?

    Huntington’s disease (HD) is a devastating neurodegenerative disorder that affects individuals and their families on multiple levels. Over the years, I’ve worked with many patients suffering from HD, and it’s difficult to overstate the physical, cognitive, and emotional toll this disease takes. Beyond the progressive motor dysfunctions that eventually rob patients of their independence, the neuropsychiatric symptoms, including severe depression, irritability, and even psychosis, can be equally debilitating. Tragically, suicide risk in this population is alarmingly high, particularly in the early stages when patients are still aware of their prognosis.

    One of the greatest challenges we face in treating Huntington’s disease is the lack of disease-modifying treatments. While therapies exist to help manage symptoms, such as tetrabenazine for chorea or antidepressants for mood disturbances, these interventions only address parts of the disease. To date, there has been little that offers hope for slowing its relentless progression.

    However, a recent article published in JAMA titled “β-Blocker Use and Delayed Onset and Progression of Huntington Disease” has introduced a glimmer of hope. The study explored the potential role of β-blockers in altering the course of HD. These medications, commonly prescribed for hypertension and cardiac conditions, may also have neuroprotective properties. According to the study, β-blocker use was associated with delayed onset and slowed progression of Huntington’s disease. The study analyzed data from a cohort of over 1,000 patients, utilizing longitudinal assessments to measure disease onset and progression. Statistical analysis revealed a significant reduction in the rate of disease progression among patients taking β-blockers compared to those who were not, with a hazard ratio of 0.78 (95% CI, 0.65–0.92; p < 0.01). This is a groundbreaking finding because it suggests a readily available and widely used class of medications could have a profound impact on a previously untreatable condition.

    The way β-blockers work to slow the progression of HD isn’t entirely clear, but it’s thought they might help by reducing brain inflammation and preventing damage caused by overstimulated nerve cells. Furthermore, they could potentially mitigate some of the psychiatric symptoms seen in HD, such as aggression and anxiety, by dampening the overactivity of the sympathetic nervous system.

    For those of us who work closely with this patient population, findings like these provide a much-needed sense of optimism. If future research confirms these results, we may see a shift in how HD is managed. Imagine being able to tell a patient, “We have a medication that might slow this disease’s progression.” That could be life-changing for so many individuals and their families.

    This study is an important reminder that even in diseases where hope seems scarce, progress is being made. For me, it reinforces why we never stop searching for answers—because even small steps forward can eventually change lives in ways we never imagined. It also underscores the importance of continued research and innovation in the field of neurodegenerative disorders. For patients with HD, their loved ones, and the clinicians who care for them, this kind of news is invaluable.

    What are your thoughts on the use of β-blockers for HD? Have you seen this approach applied in your practice or with your patients? Let’s continue the conversation and keep hope alive for those impacted by this challenging disease.

  • Is Clozapine Disease Modifying?

    Is Clozapine Disease Modifying?

    This post comes from my real world experience with treating many patients with treatment resistant schizophrenia. I wanted to create a consolidated post that goes over what we know about the benefits of clozapine in schizophrenia treatment as well as what we do not know. Clozapine is unique among antipsychotics due to its superior efficacy in treatment-resistant schizophrenia (TRS), but whether it is disease-modifying remains debated.

    1. Superior Long-term Outcomes in TRS

    • Reduced Relapse Rates: Clozapine has been shown to reduce relapse rates more effectively than other antipsychotics. For instance, a large cohort study found lower rates of rehospitalization for patients on clozapine compared to those on other second-generation antipsychotics (SGAs). The lower relapse rates may suggest stabilization of disease progression.
    • Cognitive Benefits: Several studies report improvements or stabilization in cognitive function in patients on clozapine, which contrasts with the cognitive decline often observed in schizophrenia. The preservation or improvement in cognitive function could indicate a modification of disease trajectory.

    2. Impact on Mortality and Suicidality

    • Reduced Mortality: Long-term use of clozapine has been associated with lower mortality rates in schizophrenia, both due to reduced suicide risk and fewer overall medical complications compared to other antipsychotics.
    • Suicide Prevention: Clozapine is the only antipsychotic shown to significantly reduce suicidality in schizophrenia patients, which may point to broader effects on disease severity and progression.

    3. Neurobiological Effects

    • Neuroprotection: Preclinical and human imaging studies suggest clozapine might have neuroprotective properties. Some animal models and neuroimaging studies indicate that clozapine can increase neurogenesis, reduce oxidative stress, and potentially protect against the neurodegeneration associated with chronic schizophrenia.
    • Synaptic Remodeling: There is some evidence that clozapine might positively influence synaptic plasticity. Studies suggest it might normalize the synaptic dysfunction seen in schizophrenia, which could theoretically have a disease-modifying effect by restoring some aspects of brain connectivity and function.

    4. Delay in Onset of TRS

    • Intervention Timing: There is emerging evidence suggesting that earlier introduction of clozapine (when TRS is identified) might lead to better long-term functional outcomes. This hints that clozapine could modify the disease course if used earlier in resistant cases, though direct evidence of disease modification remains scarce.

    5. Chronicity and Brain Volume Loss

    • Potential for Reduced Brain Volume Loss: Some studies indicate that clozapine may be associated with less gray matter loss over time compared to other antipsychotics. This could imply a reduction in the neuroprogressive aspects of schizophrenia.

    Limitations in Evidence

    While clozapine shows many positive outcomes, definitive evidence proving it is “disease-modifying” remains elusive:

    • Lack of RCTs Focused on Disease Modification: Most clinical trials focus on symptomatic improvement rather than long-term neurobiological changes or functional outcomes.
    • Challenges in Measuring Disease Progression: Schizophrenia is a complex, heterogeneous disorder with no clear biomarkers for progression, making it difficult to measure whether clozapine alters the underlying disease process.

    In summary, while there is compelling evidence that clozapine leads to better long-term outcomes and may have neuroprotective effects, proving it as a true disease-modifying treatment in schizophrenia requires more robust, long-term studies focused specifically on changes in the disease course.

  • Want to Slow Parkinson’s Progression? Consider the TEMPO-3 Breakthrough

    Want to Slow Parkinson’s Progression? Consider the TEMPO-3 Breakthrough

    The TEMPO-3 trial focused on the use of rasagiline in patients with early Parkinson’s disease (PD). Rasagiline is a monoamine oxidase-B (MAO-B) inhibitor, which helps to increase dopamine levels by preventing its breakdown, potentially slowing the progression of Parkinson’s disease. Here are the key findings from the TEMPO-3 trial:

    1. Slowed Progression of Symptoms: The trial found that early treatment with rasagiline at a dose of 1 mg/day slowed the progression of motor symptoms compared to delayed treatment, suggesting potential disease-modifying effects.
    2. Improvement in Quality of Life: Patients who received rasagiline earlier in their treatment course experienced an improvement in daily activities and quality of life. This was measured by tools such as the Unified Parkinson’s Disease Rating Scale (UPDRS).
    3. Well-Tolerated: Rasagiline was well-tolerated with a favorable safety profile. The side effects were mild and included headache, joint pain, and flu-like symptoms, but there were no significant safety concerns over the course of the trial.
    4. Delay in Disability: The study hinted at rasagiline’s ability to delay the onset of disability by slowing motor symptom progression, which may result in a reduced need for other symptomatic treatments earlier in the disease course.

    Overall, the TEMPO-3 trial supported rasagiline’s role as a first-line therapy in early Parkinson’s, emphasizing its benefit in delaying motor progression and potentially altering the disease course.

  • The ketogenic Diet For Mental Health

    The ketogenic Diet For Mental Health

    The ketogenic diet, primarily known for its benefits in weight loss and managing conditions like epilepsy, has been increasingly explored for its potential impact on mental health, including psychiatry. While research in this area is still emerging, some studies suggest that the ketogenic diet may offer benefits for certain psychiatric conditions. 

    1. Mood Disorders: Some research indicates that the ketogenic diet might have a positive impact on mood disorders such as depression and bipolar disorder. The diet’s ability to stabilize blood sugar levels and regulate neurotransmitters like serotonin and dopamine could contribute to mood improvement.
    2. Anxiety: The ketogenic diet’s effects on GABA (gamma-aminobutyric acid), a neurotransmitter that helps regulate anxiety, have been of interest to researchers. By increasing GABA levels, the diet may have an anxiolytic effect, potentially reducing symptoms of anxiety.
    3. Cognitive Function: Ketones produced during ketosis are an alternative fuel source for the brain. Some studies suggest that ketones may provide more efficient energy for brain cells, leading to improved cognitive function and clarity of thought. This could have implications for conditions such as ADHD and cognitive impairment.
    4. Neuroprotective Effects: Ketones have been shown to have neuroprotective properties, which could be beneficial in neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease. By providing an alternative energy source for the brain, the ketogenic diet may help protect against neuronal damage and promote brain health.
    5. Inflammation: Chronic inflammation has been linked to various psychiatric disorders. The ketogenic diet has anti-inflammatory effects, which could potentially reduce inflammation in the brain and mitigate symptoms of conditions like schizophrenia and PTSD.
    6. Gut-Brain Axis: Emerging research suggests that the gut microbiota plays a crucial role in mental health. The ketogenic diet can influence the gut microbiome, potentially improving gut health and modulating brain function through the gut-brain axis.

    While these findings are promising, it’s essential to approach the use of the ketogenic diet in psychiatry with caution. More research, including large-scale clinical trials, is needed to fully understand its efficacy, safety, and long-term effects on mental health conditions. Additionally, the ketogenic diet may not be suitable for everyone and should be implemented under the guidance of healthcare professionals, especially for individuals with pre-existing health conditions or those taking medications.